Press Releases

FDA acknowledges that data from a randomized withdrawal period of Study C602 have the potential to support an NDA submission REDWOOD CITY, Calif. , July 20, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company

REDWOOD CITY, Calif. , July 11, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced presentations at the 11 th   International Prader-Willi Syndrome

Patients demonstrated statistically significant improvements in several hormonal and cardiometabolic parameters following treatment with DCCR REDWOOD CITY, Calif. , June 13, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical

REDWOOD CITY, Calif. , June 07, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced presentations at the upcoming ENDO 2022, which is being held

REDWOOD CITY, Calif. , May 19, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced presentations at the upcoming 2022 European Congress of

REDWOOD CITY, Calif. , May 17, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar , M.D., Chief Executive Officer, will

REDWOOD CITY, Calif. , May 10, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three

Results Show Significant Improvements in Hyperphagia and PWS-Related Behaviors in DCCR-Treated Patients Presentations at the Pediatric Academic Societies 2022 Virtual Annual Meeting and Pediatric Endocrinology Society 2022 Virtual Annual Meeting REDWOOD CITY, Calif.

REDWOOD CITY, Calif. , April 01, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics , Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the closing of an underwritten public offering of 40,000,000

REDWOOD CITY, Calif. , March 31, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and announced financial results for the fourth